Relief Therapeutics Secures FDA Rare Pediatric Disease Designation for RLF-TD011

Relief Therapeutics Holding SA has announced that the U.S. FDA granted Rare Pediatric Disease designation for RLF-TD011. This treatment targets epidermolysis bullosa (EB), a rare genetic skin disorder. The drug, a hypotonic acid-oxidizing solution, aims to advance EB wound care by delivering antimicrobial and anti-inflammatory effects while preserving beneficial bacteria.

The FDA's designation reflects the urgent need for EB treatment solutions and highlights RLF-TD011’s potential. The company anticipates further engagement with the FDA to discuss development plans. Companies with this designation may become eligible for a Priority Review Voucher if certain conditions are met.